We are always evolving in an an ever changing industry.

Keep up-to-date with PrECOG by keeping an eye on our news page.

PrE0404 – Active

Now Open to Enrollment: PrE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NCT03323151